Last $104.39 USD
Change Today -2.27 / -2.13%
Volume 403.1K
ALNY On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael E. Placke Ph.D., DABT

Senior Vice President of Drug Safety and Metabolism, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

----

Background*

Dr. Michael E. Placke, Ph.D., DABT, has been Senior Vice President of Drug Safety and Metabolism at Alnylam Pharmaceuticals, Inc. since November 2013. Dr. Placke served as Vice President of Pharmaceutical Development and Chief Scientist of Ventaira Pharmaceuticals, Inc. Dr. Placke served as Senior Vice President and General Manager of Concord Ohio Drug development operations of Ricerca Biosciences, LLC. He was responsible for the operations and business performance of ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MS
The Ohio State University
BS
The Ohio State University
PhD
University of Connecticut

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $104.39 USD -2.27

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$450.0K
Mark W. Schwartz Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.